SCHEDULE 13G/A 0001510589 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 12/31/2025 0001868279 ArriVent BioPharma, Inc. 04272N102 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 Rule 13d-1(d) Hillhouse Investment Management, Ltd. E9 3929117.00 0.00 3929117.00 0.00 3929117.00 N 9.5 IA ArriVent BioPharma, Inc. 18 CAMPUS BLVD., SUITE 100, NEWTOWN SQUARE, PA, 19073-3269 This statement is filed by: This Schedule 13G is filed by Hillhouse Investment Management, Ltd, an exempted Cayman Islands company ("HIM" or the "Reporting Person") with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of ArriVent BioPharma, Inc. (the "Company") held by VSUM VI Holdings Limited ("VSUM VI"), VSUM VIII Holdings Limited ("VSUM VIII") and ARVT Holdings Limited ("ARVT"). HIM acts as the sole management company of each Hillhouse Venture Fund V, L.P. ("Venture Fund V"), Hillhouse Healthcare Fund, L.P. ("Healthcare Fund") and Hillhouse Venture Fund VI, L.P. ("Venture Fund VI"). VSUM VI is wholly owned by Venture Fund V; VSUM VIII is wholly owned by Healthcare Fund; and ARVT is wholly owned by Venture Fund VI. HIM is hereby deemed to be the beneficial owner of, and to control the voting power of, the Common Stock held by VSUM VI, VSUM VIII and ARVT. The address of the business office of the Reporting Person is Office #122, Windward 3 Building, Regatta Office Park, West Bay Road, Grand Cayman, Cayman Islands, KY1-9006. Cayman Islands Y The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 41,281,361 shares of Common Stock outstanding as of November 7, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 10, 2025. 9.5% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference. Y N See Item 2(a). Y Y Y Y Hillhouse Investment Management, Ltd. /s/ Audrey Woon 02/17/2026